Therabionic GmbH received U.S. FDA humanitarian device exemption (HDE) for its P1 device for at-home treatment of hepatocellular carcinoma, which accounts for 80% of all liver cancers, in patients who have failed first- and second-line therapies. Read More
The funding environment continues to be challenging for companies in the health care sector, and even more so for early-stage med-tech companies, delegates heard at the LSX Investival Showcase in London. Med-tech companies were told that they had to be lean, constantly work on building relationships with investors and not to give up because there is money out there for innovative technologies that can save people’s lives.
Neurophet Inc. pulled in ₩20 billion (US$15.1 million) in its series C funding round, helping roll out its AI-software suite for neurodegenerative diseases worldwide and prep its IPO on the Kosdaq which is scheduled to take place sometime in 2024.
Olympus Corp., of Center Valley, Pa., reported Nov. 9 a voluntary field corrective action for bronchoscopes prompted by complaints of endobronchial combustion during procedures that involve the use of high-frequency (HF) therapy equipment. Read More
Researchers from the University of Michigan have filed for patent protection of methods and systems to identify actual esophageal tissue changes and/or damage during cardiac ablation procedures. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbott Laboratories, Eko Health, Resonant. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Anchordx, Axlab, Biovica, Cleerly, Diacarta, GC Genome, Mauna Kea, Millar, MP Group, Neurent, Sentron, Telix, Zynex. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Therabionic. Read More
